Briquilimab

Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit) . Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema[1][2].

Product Specifications

CAS Number

[2574591-89-0]

Product Name Alternative

JSP-191; AMG-191

UNSPSC

12352203

Target

C-Kit

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/briquilimab.html

Purity

99.00

Solubility

10 mM in DMSO

Smiles

[Briquilimab]

Molecular Weight

(145.61 kDa)

References & Citations

[1]Rajni Agarwal, et al., First Report of Non-Genotoxic Conditioning with JSP191 (anti-CD117) and Hematopoietic Stem Cell Transplantation in a Newly Diagnosed Patient with Severe Combined Immune Deficiency, Blood, Volume 136, Supplement 1, 2020, Page 10, ISSN 0006-4971.|[2]Dawoon Jung, et al., Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia, Transplantation and Cellular Therapy, Volume 30, Issue 9, 2024, Pages 923.e1-923.e9, ISSN 2666-6367|[3]Pang, W. W., et al., (2019) . Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. Blood, 133 (19), 2069–2078. |[4]Kwon, H. S., et al., (2019) . Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice. Blood, 133 (19), 2104–2108.